IceCure Medical Ltd. specializes in liquid nitrogen-based cryoablation devices for minimally invasive tumor treatment, with a flagship product FDA-cleared for certain breast cancer indications. Revenue has seen modest growth driven by expanding sales in the U.S. and international markets, while net losses continue due to high R&D and commercialization costs. The company’s razor/razor blade model supports recurring disposables sales tied to system placements. Recent FDA approval of a post-marketing study represents a regulatory catalyst, but competition and financial constraints pose risks. Monitoring cash flow trends and progress on broader clinical adoption will be key.